Developing medicines for persistent post-concussion symptoms
Persistent symptoms after concussion can disrupt work, sleep and daily activities long after the initial injury. Headache, dizziness, fatigue and cognitive difficulties often overlap, leaving people with a complex care problem that is managed one symptom at a time.
Cerebrovia Therapeutics is developing medicines for persistent post-concussion symptoms. Its approach targets dysfunction in brain blood vessels, balance pathways and nerve cells, with the aim of helping patients recover daily function.
What stands out about Cerebrovia Therapeutics
Co-founder Paul Chazot developed chronic-pain and Alzheimer’s programmes over two decades of neuroscience research.
Cerebrovia’s BioCap profile describes an in-human clinical case series supporting CV-101, a combination of two established medicines for post-concussion syndrome.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.